Guided Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GTHP research report →
Price Chart
About the company
Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer.
- CEO
- Mark L. Faupel
- IPO
- 2021
- Employees
- 3
- HQ
- Peachtree Corners, GA, US
Get TickerSpark's AI analysis on GTHP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.31M
- P/E
- -5.00
- PEG
- -2.10
- P/S
- 29.70
- P/B
- -3.35
- EV/EBITDA
- -8.69
- Div Yield
- 0.00%
- Gross Margin
- 64.00%
- Op Margin
- -337.23%
- Net Margin
- -573.08%
- ROE
- 65.96%
- ROIC
- 73.63%
Latest fiscal year · YoY change
- Revenue
- $767.00K+10857.1%
- Gross Profit
- $571.00K+28450.0%
- Op Income
- $-2,372,000
- Net Income
- $-3,196,000-32.2%
- EPS
- $-0.04+5.5%
- OCF Growth
- +4.6%
- FCF Growth
- +4.4%
- 52W High
- $0.54
- 52W Low
- $0.15
- 50D MA
- $0.25
- 200D MA
- $0.28
- Beta
- 0.70
- RSI (14)
- 44
- Avg Volume
- 21.43K
No earnings-call transcripts are available for GTHP yet.
- Free Float
- 41.5%
- Shares Outstanding
- 96.54M
- Float Shares
- 40.10M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 26, 26 | Blumberg Richard P. | other | 352,000 |
| Mar 26, 26 | Blumberg Richard P. | other | 19,038 |
| Mar 26, 26 | Blumberg Richard P. | other | 1,040,000 |
| Mar 26, 26 | Blumberg Richard P. | other | 56,093 |
| Feb 25, 26 | Blumberg Richard P. | other | 1,000,000 |
| Mar 1, 26 | Blumberg Richard P. | other | 900,000 |
| Feb 25, 26 | Blumberg Richard P. | other | 1,000,000 |
| Feb 25, 26 | Blumberg Richard P. | other | 1,000,000 |
| Mar 10, 26 | Blumberg Richard P. | other | 110,000 |
| Feb 25, 26 | Blumberg Richard P. | sell | 1,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GTHP coverage
Recent articles, reports, and earnings notes.
No research on GTHP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GTHP report →Guided Therapeutics Inc. (OTCMKTS:GTHP) Shares Shorted: Short Interest Up 55.0% in September
defenseworld.net · Oct 1
Guided Therapeutics Reaches Collaborative Agreement with Türkiye's Ministry of Health to Become Primary Screening Test for Cervical Cancer
businesswire.com · Sep 9
Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor
gurufocus.com · Jul 22
Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor
businesswire.com · Jul 22
Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA
gurufocus.com · Jun 16
Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA
businesswire.com · Jun 16
Haemonetics (NYSE:HAE) vs. Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review
defenseworld.net · Apr 3
Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
businesswire.com · Mar 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.